AGI 1067
|
|
|
- CAS号:
- 216167-82-7
- 英文名:
- 4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid
- 英文别名:
- AGZ-1067;AGI 1067;SUCCINOBUCOL;Flunixin Monomer;SUCCINOBUCOL, >98%;Probucol Monosuccinate;Succinobucol(AGI 1067);Probucol monosuccinate, >98%;AGZ1067. Probucol monosuccinae;AGI-1067;PROBUCOL MONOSUCCINATE
- 中文名:
- AGI 1067
- 中文别名:
- 化合物SUCCINOBUCOL;4-(2,6-二-叔丁基-4-(2-(3,5-二-叔丁基-4-羟基苯基硫代)丙烷-2-基硫代)苯氧基)-4-氧代丁酸;4-(2,6-二-叔丁基-4-((2-((3,5-3,5-二-叔丁基-4-羟基苯基)硫基)丙-2-基)硫基)苯氧基)-4-氧代丁酸
- CBNumber:
- CB31458896
- 分子式:
- C35H52O5S2
- 分子量:
- 616.91
- MOL File:
- 216167-82-7.mol
|
|
|
AGI 1067化学性质
-
熔点:
-
139 - 142°C
-
|
-
沸点:
-
659.5±55.0 °C(Predicted)
-
|
-
密度:
-
1.13±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
Chloroform (Slightly), Methanol (Slightly)
-
|
-
酸度系数(pKa):
-
4.27±0.17(Predicted)
-
|
-
形态:
-
Solid
-
|
-
颜色:
-
White to Light Yellow
-
|
AGI 1067性质、用途与生产工艺
AGI-1067是一种新型的、酚类的细胞内外抗氧化剂，可抑制一系列参与动脉粥样硬化的促炎性基因的表达。
Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation in rabbit whole blood. Succinobucol also causes a significant reduction in whole blood aggregation in response to ADP. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. Succinobucol significantly prevents 3-NP-induced loss of SH-SY5Y cell viability, generation of reactive oxygen species, and decrease of ΔΨm. Succinobucol does not protect against 3-NP-induced inhibition of mitochondrial complex II activity, pointing to the mitigation of secondary events resultant from mitochondrial complex II inhibition. Succinobucol significantly increases (50 %) the levels of GSH in SH-SY5Y cells, which is paralleled by significant increases in glutamate cysteine ligase messenger RNA (mRNA) expression and activity. Succinobucol effectively exhibits superior inhibitory effects on cell migration and invasion activities, VCAM-1 expression and cell-cell binding of RAW 264.7 to 4T1 cells. Succinobucol also shows inhibitory effect on VCAM-1 expression in 4T1 cells and cell-cell binding of RAW 264.7 to 4T1 cancer cells.
Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 µg/mL and 20 µg/mL in rats. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice.
AGI 1067
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-14937 | AGI 1067
Succinobucol | 216167-82-7 | 5mg | 600元 |
| 2024/04/30 | HY-14937 | AGI 1067
Succinobucol | 216167-82-7 | 10mM * 1mLin DMSO | 814元 |
216167-82-7, AGI 1067 相关搜索:
- Sulfur & Selenium Compounds
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Aromatics
- 药靶配体
- 4-(2,6-二-叔丁基-4-((2-((3,5-3,5-二-叔丁基-4-羟基苯基)硫基)丙-2-基)硫基)苯氧基)-4-氧代丁酸
- 4-(2,6-二-叔丁基-4-(2-(3,5-二-叔丁基-4-羟基苯基硫代)丙烷-2-基硫代)苯氧基)-4-氧代丁酸
- 化合物SUCCINOBUCOL
- 216167-82-7
- 4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid
- Flunixin Monomer
- Inhibitor,inhibit,AGI 1067,Succinobucol,Reactive Oxygen Species,AGI1067
- 2H-1-Benzopyran-2-one,6-bromo-3,7-dihydro-
- Succinobucol(AGI 1067)
- SUCCINOBUCOL; AGI-1067; AGZ-1067; AGI1067; AGZ1067. PROBUCOL MONOSUCCINAE
- AGZ1067. Probucol monosuccinae
- AGZ-1067
- SUCCINOBUCOL, >98%
- Probucol monosuccinate, >98%
- AGI-1067;PROBUCOL MONOSUCCINATE
- 4-(2,6-di-tert-butyl-4-(2-(3,5-di-tert-butyl-4-hydroxyphenylthio)propan-2-ylthio)phenoxy)-4-oxobutanoic acid
- AGI 1067
- Probucol Monosuccinate
- Butanedioic Acid 1-[4-[[1-[[3,5-Bis(1,1-diMethylethyl)-4-hydroxyphenyl]thio]-1-Methylethyl]thio]-2,6-bis(1,1-diMethylethyl)phenyl] Ester
- SUCCINOBUCOL